2-<2-Cyan-aethyl>-1,4-benzodioxan | 2164-52-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 2-<2-Cyan-aethyl>-1,4-benzodioxan
• 英文别名: 3-(2,3-dihydro-benzo[1,4]dioxin-2-yl)-propionitrile；3-(2,3-Dihydro-1,4-benzodioxin-2-yl)propanenitrile；2-(2-cyanoethyl)-1,4-benzodioxane；3-(2,3-dihydro-1,4-benzodioxin-3-yl)propanenitrile
• CAS: 2164-52-5
• 化学式: C₁₁H₁₁NO₂
• 分子量: 189.214
• InChiKey: JQEVDRZMLSDNPS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  42.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-<2-Cyan-aethyl>-1,4-benzodioxan 生成 ethyl (1,4-benzodioxan-2-ylmethyl)acetimidate hydrochloride
  参考文献：
  名称：

  KLUGE, A. F.;STROSBERG, A. M.;WHITING, R.;CHRISTIE, G.

  摘要：

  DOI：

文献信息

• Anti-hypertensive benzodioxan derivatives
  申请人：Bouchara; Emile

  公开号：US04432984A1

  公开（公告）日：1984-02-21

  This invention relates to benzodioxanylalkylpiperidines, to processes for producing them and to the pharmaceutical compositions containing such compounds as active ingredient. This invention also relates to a method for treating hypertension in hypertensive mammals.

  本发明涉及苯二氧杂环烷基哌啶类化合物，以及制备它们的方法和包含此类化合物作为活性成分的药物组合物。本发明还涉及一种用于治疗高血压的方法，适用于高血压哺乳动物。
• Substituted heterocyclic compounds
  申请人：ADIR ET COMPAGNIE

  公开号：US20020052400A1

  公开（公告）日：2002-05-02

  The invention relates to compounds of formula (I): 1 wherein: R 1 , R 2 and R 3 are as defined in the description, X is as defined in the description, Y represents an oxygen atom, a sulphur atom, a C(H)q group, SO or S0 2 , n is equal to from 0 to 5, A represents a NR 5 R 6 or CZNR 8 R 9 group. and medicinal products containing the same are useful in treating or in preventing melatoninergic disorders.

  本发明涉及式(I)的化合物：其中：R1、R2和R3如描述中所定义，X如描述中所定义，Y代表氧原子、硫原子、C(H)q基团、SO或S02，n等于0到5，A代表NR5R6或CZNR8R9基团。含有该化合物的药物在治疗或预防褪黑素失调方面具有有用性。
• Substituted heterocyclic compounds, method for preparing and compositions containing same
  申请人：Adir et Compagnie

  公开号：US06313160B1

  公开（公告）日：2001-11-06

  The invention relates to compounds of formula (I): wherein: R1, R2 and R3 are as defined in the description, X is as defined in the description, Y represents an oxygen atom, a sulphur atom, a C(H)q group, SO or SO2, n is equal to from 0 to 5, A represents a NR5R6 group, and medicinal products containing the same which are useful in treating or in preventing melatoninergic disorders.

  本发明涉及公式(I)的化合物：其中：R1、R2和R3如描述中所定义，X如描述中所定义，Y代表氧原子、硫原子、C(H)q基团、SO或SO2，n等于0至5，A代表NR5R6基团，以及包含这些化合物的药物制剂，其在治疗或预防褪黑素失调方面有用。
• 2-(1,4-Benzodioxan-2-ylalkyl) imidazoles, their preparation and pharmaceutical compositions containing them
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0047531A1

  公开（公告）日：1982-03-17

  2-(1,4-Benzodioxan-2-ylalkyl)imidazoles having the general formula: wherein R', and R2 and R' are independently selected from the group consisting of hydrogen, and alkyl (1-6C), and wherein n is an integer equal to 0, 1 or 2, and the pharmaceutically acceptable acid addition salts thereof, are useful as affectors of the CNS, specifically as antidepressants, and are also useful as agents for the control of intraoccular pressure.

  具有通式的 2-(1,4-苯并二恶烷-2-基烷基)咪唑： 其中 R'、R2 和 R'独立地选自氢和烷基（1-6C）组成的组，n 是等于 0、1 或 2 的整数，其药学上可接受的酸加成盐可用作中枢神经系统的影响剂，特别是抗抑郁剂，还可用作控制肌内压的药物。
• Benzodioxane-imidazoline compounds, their preparation and use
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0074711A2

  公开（公告）日：1983-03-23

  Compounds of the formula and the pharmaceutically acceptable acid addition salts thereof, wherein: n is an integer equal to 0, 1, 2 or 3; R' is hydrogen, lower alkyl, optionally substituted phenyl or optionally substituted phenyl lower alkyl; each R is independently hydrogen, lower alkyl, optionally substituted phenyl, or optionally substituted phenyl lower alkyl; are a2 blockers, and, therefore, are useful in treating essential hypertension and depression and in inhibiting platelet aggregation.

  式化合物 及其药学上可接受的酸加成盐，其中 n 是等于 0、1、2 或 3 的整数； R' 是氢、低级烷基、任选取代的苯基或任选取代的苯基低级烷基； 每个 R 独立地是氢、低级烷基、任选取代的苯基或任选取代的苯基低级烷基； 是 a2 受体阻滞剂，因此 可用于治疗原发性高血压和抑郁症以及抑制血小板聚集。